This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro
by Zacks Equity Research
NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.
NVOPositive Net Change LLYNegative Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
by Ahan Chakraborty
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
AGEN Early Access Revenues Signal a New Path Ahead of Approval
by Sundeep Ganoria
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
BMYPositive Net Change MRKPositive Net Change AGENNegative Net Change
biotechs medical pharmaceuticals
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
by Sundeep Ganoria
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
BMYPositive Net Change MRKPositive Net Change AGENNegative Net Change
biotechs medical pharmaceuticals
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
by Sundeep Ganoria
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
BMYPositive Net Change MRKPositive Net Change AGENNegative Net Change
biotechs medical pharmaceuticals
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
by Zacks Equity Research
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
TEVAPositive Net Change IMCRPositive Net Change ALVONegative Net Change INDVPositive Net Change
biotechs
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
by Zacks Equity Research
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
NVSPositive Net Change BIIBPositive Net Change RHHBYNegative Net Change IONSPositive Net Change
biotechs
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
by Bryan Hayes
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
MRKPositive Net Change LLYNegative Net Change
biotechnology biotechs earnings interest-rate investing medical oncology-screening pharmaceuticals smart-health
4 Biotech Stocks Investors Should Watch in 2026
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
LQDAPositive Net Change STOKPositive Net Change IMNMNegative Net Change IMCRPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
by Ahan Chakraborty
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals